Akebia Therapeutics, Inc. AKBA · NASDAQ
$0.67 -3.67% (-$0.03)
Summary
33 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $155.5M against $54.0M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 18 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 6.9% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 4.3% a year over 5 years. Over the last 3 years it fell by 6.9% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $29.7M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.3 years of free cash flow. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio (2.2x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 4
- Sell 1
Today's price within the analysts' price targets
The average target of $1 is 49% above today's price. 58% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License Collaboration And Other Revenue 96%
- Supply Agreement 3.2%
- License Collaboration And Other Revenue, Royalties 1.1%
By region
The company reports no revenue by region.
License Collaboration And Other Revenue brings in 96% of revenue.
Segments in detail